Drug intelligence / Profile preview

rhodopsin cyclic peptide (ResQ Biotech)

Development stage: Preclinical
Lead developer: ResQ Biotech
Modality: Peptides
Administration: Intravitreal, Subretinal

Overview

ResQ Biotech's Rhodopsin program is a preclinical research initiative focused on developing cyclic peptide therapeutics for the treatment of Retinitis Pigmentosa. The program utilizes the company's proprietary engineered microbial screening platform to identify cyclic peptides that specifically bind to Rhodopsin (Rho). These peptides are designed to act as pharmacological chaperones, preventing or correcting the protein misfolding of Rhodopsin that is a primary driver of retinal degeneration and vision loss in patients with Retinitis Pigmentosa.

Other names: Rhodopsin programRhodopsin (Rho) program

Targets

RHO (Rhodopsin)

Beyond the preview

Go deeper on rhodopsin cyclic peptide (ResQ Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhodopsin cyclic peptide (ResQ Biotech).

Explore the full profile